Literature DB >> 21317040

Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus.

Amélie Guihot1, Anne Bourgarit, Guislaine Carcelain, Brigitte Autran.   

Abstract

The introduction of combined antiretroviral therapies (HAART) has reversed the fatal course of human immunodeficiency virus (HIV) infection. HAART controls virus production and, in most cases, allows the quantitative and functional immune defects caused by HIV to be reversed. Here, we review T cell homeostatic mechanisms that drive immune recovery. These homeostatic mechanisms, as well as differences in T cell antigen exposure, explain the distinct patterns of recovery for HIV-specific T cells versus T cells specific for other pathogens. Immune restoration during HAART can, however, have adverse effects. Immune restoration syndrome occurs in some patients as a result of successful but unbalanced immunity.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21317040     DOI: 10.1016/j.it.2010.12.002

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  36 in total

1.  Immune reconstitution--the footing of Chinese medicine treatment for acquired immunodeficiency syndrome.

Authors:  Jie Wang
Journal:  Chin J Integr Med       Date:  2011-05-25       Impact factor: 1.978

Review 2.  Lymph node fibroblastic reticular cells in health and disease.

Authors:  Anne L Fletcher; Sophie E Acton; Konstantin Knoblich
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

3.  A link between IL-23 and anti-CD4 autoantibody production in antiretroviral-treated HIV-infected individuals.

Authors:  Zhenwu Luo; Min Li; Fuli Mi; Zhefeng Meng; Guoqiang Du; Lisa Martin; Hui Liu; Ping Jin; David Stroncek; Sonya L Heath; Wei Jiang
Journal:  J Virol       Date:  2021-03-17       Impact factor: 5.103

4.  Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.

Authors:  Jason F Okulicz; Tuan D Le; Brian K Agan; Jose F Camargo; Michael L Landrum; Edwina Wright; Matthew J Dolan; Anuradha Ganesan; Tomas M Ferguson; Davey M Smith; Douglas D Richman; Susan J Little; Robert A Clark; Weijing He; Sunil K Ahuja
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

5.  Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.

Authors:  Livio Azzoni; Andrea S Foulkes; Cynthia Firnhaber; Xiangfan Yin; Zhi Q Xiang; Yan Li; Wendy Stevens; Robert Gross; Hildegund C J Ertl; Ian Sanne; Luis J Montaner
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

Review 6.  HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy.

Authors:  Luis M Agosto; Pradeep D Uchil; Walther Mothes
Journal:  Trends Microbiol       Date:  2015-03-09       Impact factor: 17.079

Review 7.  Cardiovascular Disease, Statins, and HIV.

Authors:  Allison Ross Eckard; Eric G Meissner; Inderjit Singh; Grace A McComsey
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

8.  Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.

Authors:  A A Herasimtschuk; B R Hansen; A Langkilde; G J Moyle; O Andersen; N Imami
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

Review 9.  Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.

Authors:  Eleanor M P Wilson; Irini Sereti
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure.

Authors:  Afam A Okoye; Louis J Picker
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.